The size of the Asia Pacific High Potency APIs Market was valued at USD 4.52 billion in 2022. It is further estimated to be growing at a CAGR of 9.1% and worth USD 6.98 billion by 2027.
High Potency Active Pharmaceutical Ingredients (HPAPI) are a group of pharmacological substances and intermediates, active at concentrations of 150 micrograms per kilogram of body weight or below. They are characterized by high specificity, so they can bind to specific receptors or specific enzymes, which can cause cancer, reproductive problems, and developmental disorders at low doses. The growth of this market is high as many new drugs have these HPAPI’s.
High Potency Active Pharmaceutical Ingredients gave rise to alternative methods of treatment by different drugs, notably cancer. After the human genome mapping, new drugs for cancer could be made not only for different cancers but also for different patients. Their production is to be done with great care since they are active even at low concentrations. They can pose grave consequences to workers if proper care is not taken during production. Special care has to be taken to prevent contamination of drugs with contaminants. So, it requires specialized equipment for handling HPAPI’s and managing air quality.
The Asia-Pacific High Potency Active Pharmaceutical Ingredients market has driving factors such as low price, growing government initiatives to increase generic medicines' usage to cut down healthcare costs, growing healthcare prices, rising number of pharmaceutical manufacturers and patients.
However, the market is constrained by factors like the lack of skilled workers, stringent regulatory requirements, and equipment's high price.
This research report on the Asia Pacific HPAPI Market has been segmented and sub-segmented into the following categories:
By Therapeutic Application:
Geographically, the Asia Pacific region is expected to be the fastest-growing region in the world. Factors such as increased funding for cancer research, the rising number of people diagnosed with cancer, and approval for the production of new drugs will boost the growth of this market in the region.
Promising companies leading the APAC High Potency API (HPAPI) Market Profiled in the Report are Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org